DL-Buthionine-S-R-sulfoximine-Buthionine-sulfoximine-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEDL-Buthionine-(S,R)-sulfoximineCat.No.:HY-106376CASNo.:5072-26-4Synonyms:Buthioninesulfoximine;BSO分?式:C?H??N?O?S分?量:222.31作?靶點(diǎn):Ferroptosis作?通路:Apoptosis儲(chǔ)存?式:Powder-20°C3yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)H2O:25mg/mL(112.46mM;ultrasonicandwarmingandheatto60°C)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM4.4982mL22.4911mL44.9822mL5mM0.8996mL4.4982mL8.9964mL10mM0.4498mL2.2491mL4.4982mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：PBSSolubility:100mg/mL(449.82mM);Clearsolution;Needultrasonic1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEBIOLOGICALACTIVITY?物活性DL-Buthionine-(S,R)-sulfoximine?氨酰半胱氨酸合成酶?物合成(glutamylcysteinesynthetasebiosynthesis)的有效抑制劑。IC50&Targetglutamylcysteinesynthetase[1]體外研究Buthioninesulfoximineisananalogsofmethioninesulfoximineandinhibitsgamma-glutamylcysteinesynthetaseabout20timesmoreeffectivelythanprothioninesulfoximineandatleast100timesmoreeffectivelythanmethioninesulfoximine[1].體內(nèi)研究TreatmentofmicebearingHT1080andHT1080/DR4xenograftswithacontinuousi.vinfusionofnontoxicdosesofD,L-Buthionine-(S,R)-sulfoximine(300and600mg/kg/day)producea60%reductionofGSHplasmalevelsandgreaterthan95%reductioninGSHtumorlevelsinbothparentalandmultidrug-resistanttumors[2].PROTOCOLAnimalMice[2]Administration[2]D,L-Buthionine-(S,R)-sulfoximineisdissolvedinsterile0.9%saline,filteredthrougha0.2-p.mpolysulfonemembranefilter,andadministeredby48-hcontinuousiv.infusionatadoseof300mg/kg/dayand600mg/kg/daystartingat24hbeforedoxorubicinadministration.InvivoGSHlevelsaftertreatmentwithD,L-Buthionine-(S,R)-sulfoximineatadoseof300mg/kgand600mg/kgfor24hasaniv.continuousinfusioninmunineplasmaandintumortissueofHT1080andHT1080/DR4xenograftsismeasured[2].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?NucleicAcidsRes.2020Sep18;48(16):9109-9123.?Small.2021Nov1;e2103984.?EcotoxicolEnvironSaf.2022,247:114263.?EcotoxicolEnvironSaf.2022Dec1;247:114263.?MolCellBiochem.2021Jan8.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].GriffithOW,etal.Potentandspecificinhibitionofglutathionesynthesisbybuthioninesulfoximine(S-n-butylhomocysteinesulfoximine).JBiolChem.1979Aug25;254(16):7558-60.[2].VanhoeferU,etal.d,l-buthionine-(S,R)-sulfoximinepotentiatesinvivothetherapeuticefficacyofdoxorubicinagainstmultidrugresistanceprotein-expressingtumors.ClinCancerRes.1996Dec;2(12):1961-8.2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEMcePdfHeightCaution:Producthasnotbeenfullyvalidat